© 2010 Myeloma UK
Charity No: SC 026116
Myeloma UK,
Broughton House,
31 Dunedin Street,
Edinburgh EH7 4JG
The way Velcade is given is set to change with the announcement that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous administration of Velcade for the treatment of myeloma. At present, Velcade is given by intravenous injections. Although very effective in treating myeloma,.....
The development of carfilzomib as a potential new treatment for myeloma has reached an important milestone with the announcement that the US Food and Drug Administration (FDA) will be reviewing a New Drug Application (NDA) for carfilzomib. Carfilzomib, a new proteasome inhibitor which works in a si.....
Myeloma UK has created a survey in order to understand more about the perspectives of myeloma patients regarding their bisphosphonate treatment. You can complete the survey here Myeloma UK Bisphosphonate Survey The survey is confidential and we anticipate that it will take 10 – 15 minutes to.....
New statistics released last week by Macmillan Cancer Support show that the median estimated survival time for people diagnosed with myeloma has increased six-fold over the past four decades. These findings were published in a special report entitled Living after Diagnosis – Median Cancer Sur.....
Scientists at The Institute of Cancer Research in London have been the first to identify specific genes that may underlie inheritable risk in myeloma, in a study funded by Myeloma UK. This research, which was recently published in the prestigious journal Nature Genetics, takes a critical step forwar.....
© 2010 Myeloma UK
Charity No: SC 026116
Myeloma UK,
Broughton House,
31 Dunedin Street,
Edinburgh EH7 4JG